Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00284791 · ClinicalTrials.gov registry record · NA
Lamotrigine in Treatment Resistant Depression in Adolescents
A NA study, sponsored by MaineHealth.
- Terminated
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT00284791 is a NA study that was terminated before completion, run by MaineHealth. The registered enrollment target is 50 participants.
The verdict
NCT00284791, a NA study, was terminated before completion, sponsored by MaineHealth.
- TERMINATED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary hypothesis of this study is that in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft). Our Primary Aim is to determine the efficacy and safety of Lamotrigine-augmentation of fluoxetine for treatment-resistant depression in adolescents. Our Secondary Aims are to characterize the factors associated with treatment-resistance for adolescents with major depression. Also to assess the relationships in the families of adolescents with major depression as they enter treatment, and to track the differences in family relationships for adolescents who respond or do not respond. We postulate that tense, frustrated, irritable, and over-involved relationships constitute a risk factor for attenuated improvement or relapse.
Interventions
- DRUG Lamotrigine (drug)
- DRUG Fluoxetine (drug)
- DRUG sertraline (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2006-01 |
| Est. Completion | 2007-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00284791
The ClinicalTrials.gov registry entry for NCT00284791 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MaineHealth, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lamotrigine (drug) is the first listed.
NCT00284791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00284791 about?
NCT00284791 is a clinical study titled "Lamotrigine in Treatment Resistant Depression in Adolescents". The primary hypothesis of this study is that in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft). Our Primary Aim is to determine the efficacy and safety of Lamotrigine-augmentation of fl...
What is the current status of trial NCT00284791?
This trial is currently terminated. It is a NA study. The enrollment target is 50 participants. The study started on 2006-01. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00284791?
The interventions under investigation include: Lamotrigine (drug) (DRUG), Fluoxetine (drug) (DRUG), sertraline (drug) (DRUG).
Who is sponsoring clinical trial NCT00284791?
This trial is sponsored by MaineHealth, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.